News

The High-impact Trials (HIT) sessions at WCN’25 promise exciting insights and findings from cutting-edge research in kidney care and related fields, including:

• The FLOW Trial investigating semaglutide’s impact on kidney outcomes and cardiovascular safety
• The REGENCY Trial on improving renal response rates in lupus nephritis with Obinutuzumab
• The ZEUS Trial evaluating ziltivekimab’s potential for cardiovascular protection in CKD

These sessions offer delegates a chance to explore advancements in chronic kidney disease (CKD), cardiovascular health, glomerular diseases, and more.

Additional groundbreaking trials featuring at the WCN’25 HIT sessions include:

• The CONFIDENCE Study examining the combined effects of finerenone and empagliflozin on CKD and type 2 diabetes
• The CONVINCE Study exploring how hemodiafiltration outperforms standard hemodialysis in reducing mortality rates and improving quality of life in end-stage kidney disease patients
• The Phase 1/2 Zigakibart Trial showing early results of zigakibart reducing proteinuria and stabilizing eGFR in IgA nephropathy
• The Pregnancy and CKD Feasibility Study exploring dietary nitrate’s role in protecting kidney function and neonatal outcomes in pregnant CKD patients
• The South Asian Platform Trial addressing glomerular diseases in South Asian populations while building a strong clinical trial network

Engage with transformative studies and their potential implications for clinical practice at the HIT sessions at WCN’25 – register for WCN’25 at the regular rate until January 8, 2025!